abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 02월 28일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제123회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Development of next-generation therapeutic antibodies through directed evolution

등록일
2019년 2월 1일 17시 14분 51초
접수번호
3071
발표코드
LIFE1-3 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 16시 : 40분
발표형식
심포지엄
발표분야
Life Chemistry - Recent Trends in Biopharmaceuticals Research
저자 및
공동저자
Sang Taek Jung
Department of Applied Chemistry, Kookmin University, Korea
IgG antibodies have been widely capitalized for therapeutics, diagnostics, and biomedical research reagents due to their outstanding target specificity and evolvability. For efficient isolation of monoclonal antibodies against highly valuable targets (e.g., soluble oncogenic targets, receptors, toxins, etc.) in a high throughput manner, we have constructed multiple human antibody libraries, which have a vast diversity of over 1× 1011, and have successfully utilized them for the isolation of monoclonal antibodies against highly challenging target antigens including G protein-coupled receptors. After binding to antigen, antibody Fc region determines therapeutic efficacy and serum half-life by the interaction with the Fc binding ligands such as FcγRs (Fc gamma receptors), serum complement molecules, and FcRn (neonatal Fc receptor). To overcome the limitation of conventional monoclonal antibodies used in the clinical practice, engineering efforts in the last several years opened a new gateway to transform IgG Fc into a highly evolvable unit for a new desired function. To enhance therapeutic efficacy and circulating half-life, we have employed a variety of genetic, cellular and evolutionary strategies and the results will be discussed.

상단으로